Genetic mechanisms and age-related macular degeneration: common variants, rare variants, copy number variations, epigenetics, and mitochondrial genetics by unknown
Liu et al. Human Genomics 2012, 6:13
http://www.humgenomics.com/content/6/1/13REVIEW Open AccessGenetic mechanisms and age-related macular
degeneration: common variants, rare variants,
copy number variations, epigenetics, and
mitochondrial genetics
Melissa M Liu1,2, Chi-Chao Chan1 and Jingsheng Tuo1*Abstract
Age-related macular degeneration (AMD) is a complex and multifaceted disease involving contributions from both
genetic and environmental influences. Previous work exploring the genetic contributions of AMD has implicated
numerous genomic regions and a variety of candidate genes as modulators of AMD susceptibility. Nevertheless,
much of this work has revolved around single-nucleotide polymorphisms (SNPs), and it is apparent that a significant
portion of the heritability of AMD cannot be explained through these mechanisms. In this review, we consider the
role of common variants, rare variants, copy number variations, epigenetics, microRNAs, and mitochondrial genetics
in AMD. Copy number variations in regulators of complement activation genes (CFHR1 and CFHR3) and glutathione
S transferase genes (GSTM1 and GSTT1) have been associated with AMD, and several additional loci have been
identified as regions of potential interest but require further evaluation. MicroRNA dysregulation has been linked to
the retinal pigment epithelium degeneration in geographic atrophy, ocular neovascularization, and oxidative stress,
all of which are hallmarks in the pathogenesis of AMD. Certain mitochondrial DNA haplogroups and SNPs in
mitochondrially encoded NADH dehydrogenase genes have also been associated with AMD. The role of these
additional mechanisms remains only partly understood, but the importance of their further investigation is clear to
elucidate more completely the genetic basis of AMD.
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cause of irreversible central vision loss in elderly popula-
tions in developed countries, and 30–50 million people
are affected worldwide [1]. In the USA, it has been esti-
mated that the prevalence of AMD is 13.4% in persons
aged 60 years and older [2]. AMD primarily affects
the photoreceptors, retinal pigment epithelium (RPE),
Bruch's membrane, and choriocapillaris in the macula,
the part of the retina responsible for central vision. It is
classically characterized by the development of drusen,
pathological extracellular deposits primarily containing
glycolipids, proteins, and cellular debris, between the
RPE and Bruch's membrane [3]. Small hard drusen can* Correspondence: tuoj@nei.nih.gov
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reproduction in any medium, provided the ordevelop with normal aging. Early AMD occurs with
more numerous and larger soft drusen in the macula,
pigmentary changes in the RPE, and thickening of
Bruch's membrane. Advanced AMD can manifest as either
geographic atrophy (dry) or neovascular/exudative (wet)
AMD. Geographic atrophy, or atrophy of the RPE, and
degeneration of the overlying photoreceptors occurs in
dry AMD. Wet AMD is characterized by the presence of
choroidal neovascularization, leading to fluid leakage,
hemorrhage, and disciform scar formation [4].
AMD is a complex and multifaceted disease involving
contributions from both genetic and environmental
influences. Epidemiological studies have identified age,
gender, race, cigarette smoking, diet, and various cardio-
vascular risk factors as potential modulators of AMD
risk, though age and cigarette smoking have been linked
most consistently [5]. Numerous genomic regions and aThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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pact AMD susceptibility. Although strong associations
with AMD have been discovered, it is apparent that a
significant portion of the heritability of AMD cannot be
explained through these known mechanisms. In a recent
meta-analysis of genome-wide association studies
(GWAS) for advanced AMD, it was estimated that cur-
rently identified loci account for approximately 55% of
the heritability of advanced AMD [6]. There is indeed a
need to explore additional factors to elucidate the
remaining genetic contributions to AMD susceptibility.
In this review, we consider the role of common variants,
rare variants, copy number variations, epigenetics,
microRNAs, and mitochondrial genetics in AMD.
Common variants
Linkage and association studies have implicated genetic
modulators of AMD risk related to many mechanistic
pathways, including oxidative stress, complement system
dysregulation, DNA repair, mitochondrial dysfunction,
neovascularization, and microglial recruitment [7]. Pro-
ducts of the complement system are present in drusen,
and genetic variations in a number of complement com-
ponents, including C2, C3, complement factor H (CFH),
factor B, and factor I, have been linked to AMD [8]. Much
of this work has revolved around single-nucleotide poly-
morphisms (SNPs). The role of SNPs in AMD has been
extensively reviewed [9-12]. The Y402H polymorphism in
CFH has been consistently demonstrated as a significant
risk factor for AMD [13-15], and it has been estimated
that the population attributable risk is between 47% and
69% [16]. SNPs in genes encoding other inflammatory
markers such as CX3CR1 [17] have also been associated
with AMD. These findings support a central role for com-
plement activation and inflammation in AMD pathogen-
esis. SNPs in age-related maculopathy susceptibility 2
(ARMS2) [18-20] and HtrA serine peptidase 1 (HTRA1)
[21,22], two genes in strong linkage disequilibrium on
chromosome 10q26 related to extracellular matrix func-
tion, are also associated with AMD susceptibility. Apoli-
proprotein E (apoE) polymorphisms modulate AMD risk
as well, with the ε4 allelic variant conferring protection
against AMD and the ε2 allelic variant increasing AMD
risk [23]. Although controversial, AMD-associated SNPs
have also been identified in excision repair cross-
complementing group 6 (ERCC6), a DNA repair gene
[24]; serpin peptidase inhibitor, clade G (C1 inhibitor),
member 1 (SERPING1), an inhibitor of the complement
component C1 [25]; and toll-like receptor 3 (TLR3) [26]
and toll-like receptor 4 (TLR4) [27], mediators of the
innate immune response.
Several recent GWAS studies have discovered novel
AMD susceptibility loci. In a British population, the
TNXB-FKBPL-NOTCH4 region was identified [28]. TheTNFRSF10A-LOC389641 and REST-C4orf14-POLR2B-
IGFBP7 loci have also been identified as susceptibility
loci for neovascular AMD in a Japanese population [29].
Variants in SKIV2L, which functions in exosome-
mediated RNA degradation, and MYRIP, which plays a
role in melanosome trafficking in the RPE, have been
associated with AMD [30]. SNPs in the FRK/COL10A1
locus, which encodes the type X collagen alpha chain,
and vascular endothelial growth factor A (VEGFA), a key
regulator of neovascularization [31], have been asso-
ciated with AMD as well [6], reiterating the role of
extracellular matrix dysfunction and aberrant angiogen-
esis in AMD pathogenesis. A SNP in tissue inhibitor of
metalloproteinases 3 (TIMP3), an inhibitor of extracellu-
lar matrix degradation, has been associated with AMD
[32]. Hepatic lipase gene (LIPC) [33], cholesterylester
transfer protein (CETP), lipoprotein lipase (LPL), and
ATP-binding cassette, sub-family A, member 1 (ABCA1),
all of which are associated with high-density lipoprotein
metabolism, were also identified in this same GWAS
study, suggesting that lipid and cholesterol dysregulation
may be relevant in AMD as well.
Rare variants
The concept that rare variants may contribute to the
heritability of common diseases is well established. In
2010, a simulation by Sobrin et al. [34] demonstrated
that common SNPs are insufficient to account for the
AMD burden in densely affected families and that rare
penetrant mutations may play a more important role.
Several rare variants contributing to AMD risk have
been identified. The rare H5 CFH haplotype, which
includes a missense mutation leading to a R1210C sub-
stitution and functionally deficient CFH, has been identi-
fied as a causative variant in certain AMD patients [35].
This example demonstrates that both common and rare
mutations in the same gene may modulate AMD risk.
Missense mutations in the FIBULIN-5 gene have also
been found in 1.7% of patients in an American AMD
population [36]. Rare variants in HEMICENTIN-1
(FIBULIN-6), which encodes an extracellular matrix pro-
tein, have also been associated with AMD [37].
Copy number variation
Copy number variation (CNV) is a common genetic
structural variation that contributes greatly to human
genetic diversity. CNVs are defined as deletions and
duplications of genomic DNA segments that are at least
one kilobase long [38]. Thousands of CNV loci have
been identified throughout the human genome [39]. Sev-
eral mechanisms have been proposed for the origination
of CNV, including nonallelic homologous recombin-
ation, nonhomologous end-joining, and fork stalling and
template switching [40]. The genomic rearrangements
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by modulating gene dosage, interrupting a gene, creating
a fusion gene, exerting position effects, or unmasking a
deleterious recessive mutation [41]. In fact, CNVs in spe-
cific genes have been linked to a variety of diseases, includ-
ing Parkinson's disease, HIV infection, psoriasis, systemic
lupus erythematosus, and a variety of neuropsychiatric dis-
eases [42-46]. Nevertheless, the role of CNV in AMD
remains incompletely understood.
It has been reported that deletions in CFH-related pro-
teins 1 and 3 (CFHR1 and CFHR3) are protective against
AMD. CFH and CFHR1–5, regulators of complement
activation, are located in a common locus in linkage
disequilibrium on the long arm of chromosome 1.
Hageman et al. identified a large deletion spanning
CFHR1 and CFHR3 and demonstrated that homozygos-
ity for this deletion conferred a protective effect, which
was particularly evident for advanced AMD [47]. Hughes
et al. identified this same deletion in two independent
cohorts and demonstrated that its protective effects
could not be attributed to the CFH Y402H genotype
[48]. It was later demonstrated that its effects are also
independent of the risk-modulating SNP in the CFH
promoter region [49]. A previously characterized CFH
haplotype, which is protective against AMD, occurs fre-
quently in homozygotes for the CFHR1 and CFHR3 de-
letion. This copy number polymorphism may indeed be
responsible for at least part of the protection conferred
by the haplotype [50]. Schmid-Kubista et al. character-
ized CNV in CFHR1 and CFHR3 in 252 AMD patients
and 249 controls using multiplex ligation-dependent
probe amplification, which allows for quantitative deter-
mination of gene copy number [51]. This study reported
novel CNVs in this locus, including homozygous dele-
tions of only CFHR1 or only CFHR3, heterozygous dele-
tion of CFHR3 only, and duplication of CFHR1 only.
Homozygous deletion of both genes decreased the odds
of AMD substantially, and the protective effects of these
CNVs were statistically significant for early AMD and
neovascular AMD. The effects of heterozygous deletion
did not achieve statistical significance, but a trend sug-
gested a gene dosage effect. It was recently estimated
that having fewer than two copies of CFHR1 and CFHR3
reduced the odds of having AMD by 43% [52]. CFHR1
and CFHR3 are regulators of the complement system
that inhibit C5 convertase and C3 convertase, respect-
ively. They are also competitive inhibitors of CFH and
interrupt the binding of CFH to C3 [49]. A recent report
suggests that the protection conferred by deletion of
CFHR1 and CFHR3 may not be independent of
rs1329428 and rs203687, two SNPs downstream of CFH
Y402H in a novel 32-kb region associated with AMD
risk [53]. This study also showed that a different deletion
CNV in a 122-kb region encompassing CFHR1 andCFHR4 was associated with protection against AMD,
independently of other CFH SNPs. The demonstrated
role of CNVs and SNPs in modulating the activity of
genes in the regulator of complement activation locus
further highlights the mechanistic importance of the
complement system in AMD pathogenesis.
CNVs in the glutathione S transferase (GST) genes are
common in human populations, and their role in a var-
iety of diseases has been investigated. GSTs are phase II
enzymes that defend against oxidative stress and detoxify
a variety of electrophilic compounds by covalent conju-
gation with glutathione [54]. Homozygous deletion of
GSTM1 and GSTT1 occurs in approximately 50% and
20% of Caucasian individuals, respectively [55]. A de-
crease in GSTT1 copy number has been linked with cor-
tical cataract [56], and deletions of GSTM1 and GSTT1
are associated with asthma [57]. Preliminary investiga-
tions have been performed to evaluate the potential role
of GST CNV in AMD. In a study by Oz et al., copy
number genotyping was performed for GSTM1, GSTT1,
and GSTP1 in 35 patients with neovascular AMD and
159 controls, and no statistically significant associations
were observed between GSTM1, GSTT1, or GSTP1 indi-
vidually and AMD [58]. However, homozygous deletions
for GSTM1/GSTT1 and GSTM1/GSTP1 in combination
were both found to significantly increase AMD risk.
Guven et al. evaluated GSTM1 and GSTT1 CNV in 120
AMD patients and 198 controls in a Turkish population
[59]. Homozygous deletion of GSTM1 was found to be
associated with AMD, and the association persisted for
dry AMD after stratification by AMD subtype. Statisti-
cally significant associations were not observed between
GSTM1 or GSTT1 genotype and neovascular AMD. A
study by Kimura et al. in a Japanese population also
reported no significant association between CNV in
GSTM1 or GSTT1 and neovascular AMD [60].
The potential role for CNV in AMD has been evalu-
ated for a number of other genes. A recent genome-wide
scan for CNVs was performed using the Affymetrix
GeneChip SNP Microarray in 400 AMD patients and
500 elderly controls. Nephrocystin 1 (NPHP1) and EGF
containing fibulin-like extracellular matrix protein
(EFEMP1) were identified as genes of interest [61].
Mutations in the NPHP1 gene have been reported in
Senior-Loken syndrome, which occurs with Leber con-
genital amaurosis, in Joubert syndrome, which may
cause retinal dystrophy, and also in juvenile nephro-
nophthisis in isolation. A deletion on chromosome 2q13
containing NPHP1, which functions in signal transduc-
tion and cytoskeleton organization, was observed in
AMD patients, but not in controls. Duplication of a re-
gion upstream of EFEMP1, a gene that is mutated in
Doyne honeycomb retinal dystrophy, was also observed
in AMD patients, but not in controls. The reported
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tions in the context of AMD remain entirely unknown
and require further investigation.
We also recently evaluated the potential role of CNV in
neovascular AMD for several candidate genes, including
CCR3, CFH, CX3CR1, ERCC6, HTRA1, VEGF, GSTM1,
and GSTT1 [62]. Quantitative copy number genotyping
was performed for each gene in 131 neovascular AMD
patients and 103 elderly controls. Previously unreported
CNVs were discovered in CCR3, CX3CR1, and ERCC6,
but after adjustment for age, no statistically significant
associations were found between CNVs in any of the eval-
uated genes and AMD. A trend in the unadjusted data
suggested that an increase in CX3CR1 copy number might
be protective against AMD. This finding complements
previously reported studies characterizing the association
between two loss-of-function SNPs in CX3CR1, V249I
and T280M [17], and elevated AMD risk. Additionally,
histological studies have demonstrated that macular
CX3CR1 protein levels are decreased in patients with
AMD [63]. Further evaluation of the role of CNV in AMD
is warranted to better understand the contribution of this
type of genetic variation to AMD risk and pathogenesis.
Epigenetics
Epigenetic modifications, or covalent modifications of
genomic DNA that affect gene expression while preserv-
ing the DNA sequence, have also been investigated as po-
tential genetic modulators of human disease. Methylation
at the C5 position of cytosine is a common epigenetic
modification that decreases gene transcription, and cyto-
sine methylation in CpG dinucleotides can occur in clus-
ters throughout the genome known as CpG islands.
Covalent histone modifications, including methylation,
acetylation, sumoylation, and phosphorylation, are also
epigenetic modulators that affect gene transcription. Aber-
rant methylation patterns are associated with genomic in-
stability and recognized as early genetic changes in certain
tumors [64]. Loss of imprinting, or the epigenetic modifi-
cations that are inherited from parental chromosomes,
has also been implicated in several conditions, including
Beckwith-Wiedemann syndrome and Prader-Willi syn-
drome, and DNA methylation defects in T cells may con-
tribute to systemic lupus erythematosus [65]. In
experimental models, epigenetic patterns have also been
shown to change with parental or embryonic exposure to
dietary and environmental factors [66]. Global levels of
genomic DNA methylation also decrease with age [67].
Based on these findings, epigenetic modifications may
indeed serve as a genetic mechanism by which aging and
environmental exposures modulate disease risk. These
effects may be particularly pronounced in complex dis-
eases of aging with demonstrated environmental contribu-
tions, such as AMD. The study of the role of epigeneticsin AMD pathogenesis has only recently begun. A DNA
methylation analysis was recently performed in three pairs
of monozygotic twins with disparate AMD phenotypes to
scan for genome-wide differences in methylation patterns.
There were 256 genes with hypomethylated CpG sites and
744 genes with hypermethylated CpG sites in the twins
with AMD (L Wei, unpublished work). The authors re-
cently identified the IL-17 RC promoter, which is hypo-
methylated in AMD patients, as a locus of interest.
Hypomethylation at this locus results in elevated expres-
sion levels of IL-17 RC in the peripheral blood cells and
macular lesions of AMD patients (L Wei, unpublished
work). The mechanistic implications of these differences
require further investigation.
It is clear that environmental and dietary factors have
a significant impact on AMD risk and progression. The
Age-Related Eye Disease Study (AREDS) demonstrated
that dietary supplements containing antioxidants such as
zinc, beta-carotene, vitamin C, and vitamin E helped to
decrease the risk of progression from intermediate to
advanced AMD by 25% over 5 years [68]. Preliminary
studies evaluating lutein, zeaxanthin, omega-3 fatty
acids, and B vitamins have suggested that these com-
pounds may confer protective effects as well [69]. A case
series of monozygotic twin pairs with disparate AMD
phenotypes has also been reviewed to assess the impact
of behavioral and nutritional factors on AMD [70].
Twins with more advanced AMD tended to be heavier
smokers and consumed less dietary vitamin D, betaine,
and methionine. The modulatory effects of smoking and
antioxidant supplementation on AMD confirm the crit-
ical role of oxidative stress in AMD pathogenesis. Add-
itional studies are needed to investigate whether DNA
methylation changes or other epigenetic modifications
play a contributory role as well, but chronic low levels of
antioxidant micronutrients may lead to changes in DNA
methylation, synthesis, and repair.
MicroRNAs
MicroRNAs are 19–25-nucleotide single-stranded non-
coding RNAs that post-transcriptionally downregulate
gene expression by binding the 30 untranslated region
(30-UTR) of target mRNAs and marking them for cleav-
age by the RNA-induced silencing complex. MicroRNA
genes are transcribed and trimmed to form pre-
microRNAs with characteristic hairpin structures. Pre-
microRNAs are cleaved by Drosha, exported from the
nucleus, and processed again by Dicer in the cytoplasm
to yield mature microRNAs [71]. It has been predicted
that 30% of human genes may be regulated by micro-
RNAs [72]. The role of microRNAs has been demon-
strated in several contexts, including cancer [73] and
immune function [74], and it is being investigated in
AMD as well [75].
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microRNAs miR-9, miR-125b, miR-146a, and miR-155
are upregulated in both AMD and Alzheimer's disease
and that miR-146a and miR-155 target the 30-UTR of
CFH, thereby downregulating CFH [76]. A reduction in
the Dicer1 enzyme and concomitant rise in Alu RNA
has also been linked to the RPE degeneration in AMD
patients with geographic atrophy [77]. Some studies have
investigated the role of microRNAs in ocular neovascu-
larization. It has been shown that microRNAs miR-31,
miR-150, and miR-184 are significantly reduced in an
ischemia-induced mouse model of retinal neovasculari-
zation and in a laser-induced mouse model of choroidal
neovascularization in the absence of ischemia [78].
Intraocular injection with pre-miR-31 or pre-miR-150
significantly reduced the size of choroidal neovascular
lesions. A recent study also demonstrated that knock-
down of miR-23 and miR-27, which downregulate the
antiangiogenic factors Sprouty2 and Sema6A, is protect-
ive against laser-induced choroidal neovascularization
[79]. MicroRNA23a has also been found to be decreased
in RPE cells from AMD donor eyes, and in ARPE-19
cells, it has been shown that antisense-mediated inhib-
ition of miR-23a reduced cell growth and that the
addition of a miR-23a mimic reduced H2O2-induced oxi-
dative damage and Fas-mediated apoptosis [80]. As
choroidal neovascularization and oxidative stress are
hallmarks in AMD, these microRNAs may provide
insights for the development of novel therapeutics.
Mitochondrial genetics
Cells have several defense mechanisms against oxida-
tive stress, including antioxidant compounds and
enzymes and DNA repair machinery, but tissue dam-
age can occur when these mechanisms are over-
whelmed, and oxidative stress is believed to be a
significant mechanistic contributor in AMD [81]. The
retina is particularly susceptible to oxidative damage
because it is among the most metabolically active tis-
sues by weight in the body and because it is constantly
under photochemical stress. Photoreceptors contain
abundant mitochondria and produce high concentra-
tions of reactive oxygen species (ROS) that when inad-
equately controlled lead to tissue damage, particularly
in the underlying RPE. ROS can cause damage to
macromolecules and organelles throughout the cell,
but oxidative stress-induced mitochondrial DNA
(mtDNA) damage has been especially studied as a
pathogenic mechanism in AMD [82,83].
There are several factors that contribute to this
phenomenon, including the localization of cell respir-
ation reactions and ROS production in the mitochon-
dria and decreased mtDNA repair mechanisms relative
to nuclear DNA (nDNA) repair mechanisms, thoughsome mtDNA damage can be corrected via base exci-
sion repair and mismatch repair [84]. The accumulation
of mtDNA defects leads to an overall decline in mito-
chondrial function over time. In rodent RPE and
choroid, the levels of the oxidative DNA damage marker
8-hydroxy-20-deoxy-guanosine (8-OHdG) and the levels
of deleted mtDNA increased with age, while the levels of
certain DNA repair enzymes correspondingly decrease
with age [85]. As a consequence of decreased mtDNA
repair capacity, oxidative stress has been shown to pre-
ferentially damage mtDNA over nDNA in human RPE
cells [86]. Accumulation of mtDNA deletions and cyto-
chrome c oxidase deficiency has also been demonstrated
with aging in human cone photoreceptors, particularly
in the fovea [87]. The number of mtDNA rearrange-
ments and deletions is also greater for the retina than
for peripheral blood cells, in both AMD patients and
age-matched normal controls [88], supporting the im-
portance of the metabolically active retinal microenvir-
onment and oxidative stress in mtDNA changes. In
AMD retinas, mtDNA lesions are increased throughout
the mitochondrial genome, and the degree of damage
exceeds that which is seen in mtDNA with normal
aging [89].
To more specifically characterize the mtDNA changes
in AMD, several studies have compared mtDNA varia-
tions between AMD patients and normal controls. Jones
et al. used restriction fragment length polymorphism
analysis to determine mtDNA haplogroups for 3,302
Australian individuals from the Blue Mountains Eye
Study, 317 of whom had either early or late AMD [90].
After adjusting for age, sex, and smoking status, mtDNA
haplogroup H, the most prevalent haplogroup for Euro-
pean populations, was found to be protective against
AMD, especially early AMD, and large soft drusen.
Conversely, mtDNA haplogroup U was associated with
increased RPE abnormalities. Udar et al. analyzed retinal
mtDNA from the eyes of 11 AMD patients and 10 eld-
erly controls and showed that AMD mtDNA had higher
levels of oxidative damage, as evidenced by 8-OHdG
staining, and a higher frequency of SNPs [91]. SNPs in
the noncoding mtDNA control region at T16126C,
T16126C+G13368A, A4917G+A73G, and T3197C+
A12308G were strongly associated with AMD, and these
SNPs correlated with mtDNA haplogroups J, T, and U.
The A4917G SNP in the mitochondrially encoded
NADH dehydrogenase gene, which defines mtDNA hap-
logroup T, was also shown in separate studies to be asso-
ciated with increased risk of AMD, potentially by
disrupting cell respiration and increasing the production
of ROS [92,93]. Carrying the A11812G and A4917G
SNPs, both of which lie in NADH ubiquinone oxidore-
ductase genes, has been associated with a 2.5-fold
elevated risk of developing advanced AMD [93].
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AMD is a significant cause of irreversible blindness in
the elderly, and the global burden of this disease is ever-
growing as populations age. The genetic basis of this dis-
ease is only partially understood. However, it is hoped
that further investigations may lead to the identification
of novel therapeutic pathways. Technological advance-
ments have facilitated the exploration of mitochondrial
genetics, epigenetic modifications, and genetic structural
variations such as CNV in not only AMD but also a var-
iety of other common diseases. The role of CNV in
AMD has thus far proven to be moderate, but the evi-
dence suggests that further studies are warranted. The
preliminary experiments evaluating epigenetic modifica-
tions in AMD require replication in independent study
populations, and additionally, given the demonstrated
importance of the retinal microenvironment in AMD, it
may be illustrative to evaluate these types of genetic
modifications in retinal tissues, not only in peripheral
blood mononuclear cells. There is a wide array of het-
erogeneity in AMD phenotype and response to therapy,
and a more complete understanding of the genetics of
AMD is critical. Many SNPs have been reproducibly
demonstrated in AMD risk and pathogenesis, but there
are clearly additional genetic mechanisms that remain to
be identified. Common variants explain approximately
55% of the heritability of AMD. Mechanisms such as
rare variants, copy number variations, epigenetics, and
mitochondrial inheritance may contribute to the missing
heritability. Considering more fully the predisposing
genetic factors in AMD may ultimately help to identify
high risk populations, predict disease progression, and
anticipate response to personalized therapy.
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